Communiqués Zentalis Pharmaceuticals, Inc.

Actions

ZNTL

US98943L1070

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/08/2026			Varia. 5j.	Varia. 1 janv.
4,220 ^USD	-15,60%		-10,97%	+212,59%

07/08	ZENTALIS PHARMACEUTICALS, INC. : Wedbush n'est pas inspiré par le dossier	ZM
07/08	ZENTALIS PHARMACEUTICALS, INC. : Morgan Stanley neutre sur le dossier	ZM

Communiqués

07/08	Zentalis Pharmaceuticals : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates	AQ
03/08	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
20/07	Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026	AQ
17/07	Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026	AQ
01/06	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
27/05	Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy	AQ
21/05	Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026	AQ
13/05	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
12/05	Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress	AQ
05/05	Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer	AQ
04/05	Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	AQ
01/05	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
21/04	Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer	AQ
17/04	Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026	AQ
09/04	Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer	AQ
01/04	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
26/03	Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates	AQ
17/03	Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026	AQ
18/02	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
03/02	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference	AQ
12/01	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026	PR
06/01	Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026	AQ
10/11	Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress	AQ
03/11	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ